913 reports of this reaction
1.8% of all OXYBUTYNIN reports
#12 most reported adverse reaction
APPLICATION SITE ERYTHEMA is the #12 most commonly reported adverse reaction for OXYBUTYNIN, manufactured by Allergan, Inc.. There are 913 FDA adverse event reports linking OXYBUTYNIN to APPLICATION SITE ERYTHEMA. This represents approximately 1.8% of all 51,990 adverse event reports for this drug.
OXYBUTYNIN has an overall safety score of 78 out of 100. Patients taking OXYBUTYNIN who experience application site erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE ERYTHEMA is a less commonly reported adverse event for OXYBUTYNIN, but still significant enough to appear in the safety profile.
In addition to application site erythema, the following adverse reactions have been reported for OXYBUTYNIN:
The following drugs have also been linked to application site erythema in FDA adverse event reports:
APPLICATION SITE ERYTHEMA has been reported as an adverse event in 913 FDA reports for OXYBUTYNIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE ERYTHEMA accounts for approximately 1.8% of all adverse event reports for OXYBUTYNIN, making it a notable side effect.
If you experience application site erythema while taking OXYBUTYNIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.